Last reviewed · How we verify

Codeine paracetamol

Napp Pharmaceuticals Limited · FDA-approved active Small molecule

Codeine acts as a weak opioid agonist while paracetamol inhibits prostaglandin synthesis, together providing analgesic and antipyretic effects.

Codeine acts as a weak opioid agonist while paracetamol inhibits prostaglandin synthesis, together providing analgesic and antipyretic effects. Used for Moderate acute pain, Mild to moderate chronic pain.

At a glance

Generic nameCodeine paracetamol
Also known asCo-codamol tablets
SponsorNapp Pharmaceuticals Limited
Drug classOpioid analgesic combination
TargetOpioid receptors (μ, δ, κ); cyclooxygenase (COX-1, COX-2)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Codeine binds to opioid receptors in the central nervous system to reduce pain perception, while paracetamol (acetaminophen) inhibits cyclooxygenase enzymes to decrease prostaglandin production, lowering pain and fever. The combination provides synergistic analgesia for moderate pain relief with lower opioid doses than codeine alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results